2009 Fiscal Year Final Research Report
Development of PEGylated thiol modified protein drugs for the treatment of sepsis
| Project/Area Number |
20790402
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
KATSUMI Hidemasa Kyoto Pharmaceutical University, 薬学部, 助教 (30434666)
|
|---|
| Research Collaborator |
YAMAMOTO Akira 京都薬科大学, 薬学部, 教授 (00166779)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Keywords | ドラッグデリバリー |
|---|
| Research Abstract |
To prevent septic shock and hepatitis, prolonged delivery of reduced thiols to the blood circulation was performed in animals by a bolus intravenous injection of polyethylene glycol (PEG)-conjugated thiols modified serum albumin (PEG-BSA-SH). PEG-BSA-SH exhibited a prolonged retention in the plasma after intravenous injection into mice. PEG-BSA-SH also effectively suppressed the septic shock and hepatitis in the sepsis mouse or rat model. These findings indicate that PEG-BSA-SH is a promising compound for the treatment of septic shock and hepatitis.
|
